GLPwatch
Papers (10382)
Page 116 of 174, ranked by citation count.
- Liraglutide Protects Pancreatic Islet From Ischemic Injury by Reducing Oxidative Stress and Activating Akt Signaling During Cold Preservation to Improve Islet Transplantation Outcomes.
- Transcriptomics and proteomics characterizing the antioxidant mechanisms of semaglutide in diabetic mice with cognitive impairment.
- Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
- Tirzepatide and kidney function: an intriguing and promising observation.
- Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
- How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion.
- Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis.
- Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.
- [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
- Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
- In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.
- Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.
- A Study on Weight Loss Cause as per the Side Effect of Liraglutide.
- Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.
- Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line.
- Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.
- Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration.
- Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.
- Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus.
- Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.
- Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
- Liraglutide restores late cardioprotective effects of remote preconditioning in diabetic rats via activation of hydrogen sulfide and nuclear factor erythroid 2-related factor 2 signaling pathway.
- Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
- Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.
- Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.
- Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity.
- Alzheimer's disease and type 2 diabetes: what is the connection?
- Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.
- White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.
- Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
- Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
- Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K/Akt pathway.
- Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
- Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.
- Combination of metformin with liraglutide in treating HAIR-AN syndrome in children<b>:</b> A case report and literature review.
- Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression.
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.
- A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
- Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.
- Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.
- Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.
- Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study.
- Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
- Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
- Exenatide induced acute kidney injury.
- Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
- Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
- Divergent effects of exendin-4 and interleukin-6 on rat colonic secretory and contractile activity are associated with changes in regional vagal afferent signaling.
- Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes.
- The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
- Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
- Liraglutide alleviated alpha-pyrrolidinovalerophenone (α-PVP) induced cognitive deficits in rats by modifying brain mitochondrial impairment.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Exenatide modulates visual cortex responses.
- Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?
- Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
- Renoprotective effects of dulaglutide in patients with T2DM and CKD.